	US 12,403,193 B2
	Allergen desensitization method
Christophe Dupont, Clamart (FR); Pierre-Henri Benhamou, Paris (FR); and Bertrand Dupont, Aix en Provence (FR)
Assigned to DBV TECHNOLOGIES, Châtillon (FR); ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS, Paris (FR); and UNIVERSITÉ PARIS CITÉ, Paris (FR)
Filed by DBV Technologies, Châtillon (FR); Assistance Publique-Hôpitaux De Paris, Paris (FR); and Université Paris Cité, Paris (FR)
Filed on Feb. 14, 2024, as Appl. No. 18/441,930.
Application 18/441,930 is a continuation of application No. 17/523,648, filed on Nov. 10, 2021, granted, now 11,931,411.
Application 17/523,648 is a continuation of application No. 16/937,444, filed on Jul. 23, 2020, granted, now 11,202,826, issued on Dec. 21, 2021.
Application 16/937,444 is a continuation of application No. 16/395,206, filed on Apr. 25, 2019, granted, now 10,758,610, issued on Sep. 1, 2020.
Application 16/395,206 is a continuation of application No. 16/036,919, filed on Jul. 16, 2018, granted, now 10,272,151, issued on Apr. 30, 2019.
Application 16/036,919 is a continuation of application No. 15/367,078, filed on Dec. 1, 2016, granted, now 10,022,439, issued on Jul. 17, 2018.
Application 15/367,078 is a continuation of application No. 12/745,870, granted, now 9,539,318, issued on Jan. 10, 2017, previously published as PCT/FR2008/052199, filed on Dec. 3, 2008.
Claims priority of provisional application 61/084,305, filed on Jul. 29, 2008.
Claims priority of application No. 0759503 (FR), filed on Dec. 3, 2007.
Prior Publication US 2024/0181046 A1, Jun. 6, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/35 (2006.01); A61K 9/00 (2006.01); A61K 9/70 (2006.01); A61K 39/00 (2006.01); A61K 39/36 (2006.01)

CPC A61K 39/35 (2013.01) [A61K 9/0014 (2013.01); A61K 9/7007 (2013.01); A61K 39/36 (2013.01); A61K 9/7023 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01)]

18 Claims

1. A method for epicutaneous desensitization of a subject allergic to egg, the method comprising:

a) epicutaneously exposing the subject to an egg allergen, without an adjuvant, and generating an immune reaction in the subject by applying a dose of the egg allergen, without an adjuvant, onto an intact region of skin of the subject; and

b) repeatedly applying the egg allergen, without an adjuvant, to an intact region of the skin of the subject, at a dose, frequency or for an application time adapted to sustain the immune reaction, the exposure and sustained reaction leading to desensitization of the subject;

wherein the egg allergen is applied, without an adjuvant, by a cutaneous occlusive device configured to ensure contact between the allergen and the region of skin, and wherein said dose of egg allergen is comprised between 0.1 and 1,000 μg/cm²of a surface area of the device.